HRP20160641T1 - Fuzionirani triciklički spojevi kao inhibitori raf kinaze - Google Patents
Fuzionirani triciklički spojevi kao inhibitori raf kinaze Download PDFInfo
- Publication number
- HRP20160641T1 HRP20160641T1 HRP20160641TT HRP20160641T HRP20160641T1 HR P20160641 T1 HRP20160641 T1 HR P20160641T1 HR P20160641T T HRP20160641T T HR P20160641TT HR P20160641 T HRP20160641 T HR P20160641T HR P20160641 T1 HRP20160641 T1 HR P20160641T1
- Authority
- HR
- Croatia
- Prior art keywords
- heterocyclyl
- alkyl
- heteroaryl
- alkynyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085146 WO2013097224A1 (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160641T1 true HRP20160641T1 (hr) | 2016-09-23 |
Family
ID=48696279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160641TT HRP20160641T1 (hr) | 2011-12-31 | 2011-12-31 | Fuzionirani triciklički spojevi kao inhibitori raf kinaze |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9273046B2 (h) |
| EP (2) | EP2797888B1 (h) |
| JP (1) | JP5868521B2 (h) |
| KR (1) | KR101713391B1 (h) |
| CN (1) | CN103596926B (h) |
| AU (1) | AU2011384857B2 (h) |
| BR (1) | BR112014013108B1 (h) |
| CA (1) | CA2856347C (h) |
| CY (1) | CY1118226T1 (h) |
| DK (1) | DK2797888T3 (h) |
| EA (1) | EA025597B1 (h) |
| ES (1) | ES2588775T3 (h) |
| HR (1) | HRP20160641T1 (h) |
| HU (1) | HUE029656T2 (h) |
| IL (1) | IL233364A (h) |
| IN (1) | IN2014DN06166A (h) |
| LT (1) | LT2797888T (h) |
| ME (1) | ME02529B (h) |
| MX (1) | MX352617B (h) |
| NZ (1) | NZ624068A (h) |
| PL (1) | PL2797888T3 (h) |
| PT (1) | PT2797888T (h) |
| RS (1) | RS55196B1 (h) |
| SG (1) | SG11201401725SA (h) |
| SI (1) | SI2797888T1 (h) |
| SM (1) | SMT201600302B (h) |
| WO (1) | WO2013097224A1 (h) |
| ZA (1) | ZA201405555B (h) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA025597B1 (ru) | 2011-12-31 | 2017-01-30 | Бейджен, Лтд. | КОНДЕНСИРОВАННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Raf КИНАЗЫ |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| BR112015032539B1 (pt) * | 2013-06-28 | 2022-07-12 | Beigene, Ltd | Compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase e composição farmacêutica compreendendo os referidos compostos |
| WO2015089809A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| WO2015176267A1 (en) * | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| GB201416186D0 (en) * | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| KR20240049684A (ko) * | 2015-04-15 | 2024-04-16 | 베이진 엘티디 | B-raf 키나아제 억제제의 말레에이트 염, 결정질 형태, 제조방법, 및 이의 용도 |
| JP6175519B2 (ja) * | 2016-01-04 | 2017-08-09 | ベイジーン リミテッド | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 |
| EP3481393B1 (en) * | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
| IL297717A (en) | 2016-12-01 | 2022-12-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| KR102564201B1 (ko) | 2016-12-23 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| BR112022012110A2 (pt) | 2019-12-19 | 2022-12-13 | Arvinas Operations Inc | Compostos e métodos para a degradação direcionada de receptor androgênico |
| CN116601150A (zh) | 2020-07-28 | 2023-08-15 | 爵士制药爱尔兰有限公司 | 稠合双环raf抑制剂及其使用方法 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| CA3200386A1 (en) * | 2020-12-29 | 2022-07-07 | Seo Jung Han | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| WO2023049060A1 (en) * | 2021-09-21 | 2023-03-30 | Merck Sharp & Dohme Llc | Allosteric modulators of nicotinic acetylcholine receptors |
| WO2023209611A1 (en) | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| WO2023212071A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Combination and the use thereof |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068773A1 (en) | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| ES2527118T3 (es) | 2003-12-19 | 2015-01-20 | Plexxikon Inc. | Compuestos y procedimientos de desarrollo de moduladores de Ret |
| AU2005316668B2 (en) * | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US7846941B2 (en) | 2005-05-17 | 2010-12-07 | Plexxikon, Inc. | Compounds modulating c-kit and c-fms activity and uses therefor |
| US7566716B2 (en) | 2005-05-20 | 2009-07-28 | Array Biopharma Inc. | Imidazopyrazines as Raf inhibitor compounds |
| EP3088400A1 (en) | 2005-06-22 | 2016-11-02 | Plexxikon Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
| CA2620864A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| KR20080074220A (ko) * | 2005-12-08 | 2008-08-12 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 키나아제 억제 활성을 갖는 비시클릭 화합물 |
| WO2007136573A2 (en) | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| CA2661334C (en) * | 2006-08-23 | 2011-11-29 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
| MX2009002010A (es) | 2006-09-06 | 2009-03-05 | Hoffmann La Roche | Derivados de heteroarilo como inhibidores de la proteina cinasa. |
| JP2010502706A (ja) * | 2006-09-07 | 2010-01-28 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害活性を有するフェネチルアミド誘導体 |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| KR20090130345A (ko) * | 2007-05-04 | 2009-12-22 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 화합물 및 조성물 |
| BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| EA025597B1 (ru) | 2011-12-31 | 2017-01-30 | Бейджен, Лтд. | КОНДЕНСИРОВАННЫЕ ТРИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Raf КИНАЗЫ |
| KR20240049684A (ko) | 2015-04-15 | 2024-04-16 | 베이진 엘티디 | B-raf 키나아제 억제제의 말레에이트 염, 결정질 형태, 제조방법, 및 이의 용도 |
-
2011
- 2011-12-31 EA EA201491305A patent/EA025597B1/ru not_active IP Right Cessation
- 2011-12-31 US US14/369,379 patent/US9273046B2/en active Active
- 2011-12-31 KR KR1020147018101A patent/KR101713391B1/ko active Active
- 2011-12-31 AU AU2011384857A patent/AU2011384857B2/en active Active
- 2011-12-31 CA CA2856347A patent/CA2856347C/en active Active
- 2011-12-31 HU HUE11879096A patent/HUE029656T2/en unknown
- 2011-12-31 WO PCT/CN2011/085146 patent/WO2013097224A1/en active Application Filing
- 2011-12-31 ES ES11879096.3T patent/ES2588775T3/es active Active
- 2011-12-31 LT LTEP11879096.3T patent/LT2797888T/lt unknown
- 2011-12-31 BR BR112014013108-2A patent/BR112014013108B1/pt active IP Right Grant
- 2011-12-31 EP EP11879096.3A patent/EP2797888B1/en active Active
- 2011-12-31 NZ NZ624068A patent/NZ624068A/en unknown
- 2011-12-31 HR HRP20160641TT patent/HRP20160641T1/hr unknown
- 2011-12-31 JP JP2014549294A patent/JP5868521B2/ja active Active
- 2011-12-31 PL PL11879096.3T patent/PL2797888T3/pl unknown
- 2011-12-31 SG SG11201401725SA patent/SG11201401725SA/en unknown
- 2011-12-31 SI SI201130852A patent/SI2797888T1/sl unknown
- 2011-12-31 ME MEP-2016-172A patent/ME02529B/me unknown
- 2011-12-31 RS RS20160713A patent/RS55196B1/sr unknown
- 2011-12-31 EP EP16167542.6A patent/EP3124472B1/en active Active
- 2011-12-31 PT PT118790963T patent/PT2797888T/pt unknown
- 2011-12-31 DK DK11879096.3T patent/DK2797888T3/en active
- 2011-12-31 CN CN201180069798.XA patent/CN103596926B/zh active Active
- 2011-12-31 IN IN6166DEN2014 patent/IN2014DN06166A/en unknown
- 2011-12-31 MX MX2014007829A patent/MX352617B/es active IP Right Grant
-
2014
- 2014-06-25 IL IL233364A patent/IL233364A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05555A patent/ZA201405555B/en unknown
-
2016
- 2016-01-22 US US15/004,311 patent/US9895376B2/en active Active
- 2016-09-05 CY CY20161100869T patent/CY1118226T1/el unknown
- 2016-09-06 SM SM201600302T patent/SMT201600302B/it unknown
-
2018
- 2018-01-29 US US15/882,064 patent/US10576087B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160641T1 (hr) | Fuzionirani triciklički spojevi kao inhibitori raf kinaze | |
| HRP20211617T1 (hr) | Benzo[b]tiofenski spojevi kao agonisti sting | |
| ME02855B (me) | KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| HRP20170217T1 (hr) | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze | |
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20241197T1 (hr) | Makrociklični spojevi i primjene istih | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| HRP20240300T1 (hr) | Spoj [1,2,4]triazolo[1,5-a]piridina kao inhibitor jak i njegova primjena | |
| HRP20150184T1 (hr) | Makrocikliäśki spoj i postupci za njegovu proizvodnju | |
| ME00876B (me) | 4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| HRP20160374T1 (hr) | Farmaceutski spojevi | |
| EA200601192A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| HRP20130942T1 (hr) | Aminodiazepini kao modulatori toll-u sliäśnih receptora | |
| ME02409B (me) | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| RU2012157293A (ru) | Макроциклические соединения, применимые в качестве ингибиторов гистондеацетилаз | |
| DK2966079T1 (da) | Pyridopyrimidin eller pyrimidopyrimidinforbindelse, fremstillingsmetode, pharmaceutisk præparat og anvendelse heraf | |
| HRP20170025T1 (hr) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda |